UBS Group
FDMT icon

UBS Group’s 4D Molecular Therapeutics FDMT Stock Holding History

UBS Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41M Buy
256,673
+98,553
+62% +$960K ﹤0.01% 4573
2026
Q1 		$1.47M Sell
158,120
-73,172
-32% -$637K ﹤0.01% 5242
2025
Q4 		$1.73M Buy
231,292
+136,392
+144% +$1.38M ﹤0.01% 5097
2025
Q3 		$825K Sell
94,900
-1,619
-2% -$9.68K ﹤0.01% 5723
2025
Q2 		$358K Sell
96,519
-139,926
-59% -$492K ﹤0.01% 6290
2025
Q1 		$764K Buy
236,445
+138,881
+142% +$654K ﹤0.01% 5513
2024
Q4 		$543K Buy
97,564
+17,275
+22% +$136K ﹤0.01% 5776
2024
Q3 		$868K Buy
80,289
+13,149
+20% +$218K ﹤0.01% 4778
2024
Q2 		$1.41M Sell
67,140
-307,050
-82% -$7.7M ﹤0.01% 4104
2024
Q1 		$11.9M Buy
374,190
+288,139
+335% +$7.35M ﹤0.01% 2125
2023
Q4 		$1.74M Buy
86,051
+41,154
+92% +$541K ﹤0.01% 3970
2023
Q3 		$572K Sell
44,897
-8,953
-17% -$150K ﹤0.01% 4557
2023
Q2 		$973K Buy
53,850
+1,451
+3% +$26.7K ﹤0.01% 4280
2023
Q1 		$901K Buy
52,399
+11,671
+29% +$227K ﹤0.01% 4210
2022
Q4 		$905K Buy
+40,728
New +$629K ﹤0.01% 4167
2022
Q3 		– Sell
-35
Closed – – 10504
2022
Q2 		$0 Sell
35
-70,199
-100% -$682K ﹤0.01% 10491
2022
Q1 		$1.06M Buy
70,234
+884
+1% +$13.9K ﹤0.01% 4034
2021
Q4 		$1.52M Buy
69,350
+68,094
+5,421% +$1.67M ﹤0.01% 3997
2021
Q3 		$34K Buy
+1,256
New +$35.8K ﹤0.01% 6640
2021
Q2 		– Sell
-20,592
Closed -$893K – 9494
2021
Q1 		$893K Buy
+20,592
New +$912K ﹤0.01% 4376

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

UBS Group's FDMT Position: Q2 2026 in Review

UBS Group increased its 4D Molecular Therapeutics (FDMT) stake by 62% in Q2 2026, buying an estimated $960K and bringing the position to 256,673 shares worth $3.41M. The position accounts for ﹤0.01% of the portfolio, ranked #4573.

UBS Group first reported a position in FDMT in Q1 2021 and has held it in 20 quarters since. The position peaked at $11.9M in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • UBS Group held 256,673 shares of 4D Molecular Therapeutics worth $3.41M as of Q2 2026.
  • UBS Group bought 98,553 4D Molecular Therapeutics shares in Q2 2026, an estimated $960K.
  • 4D Molecular Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4573 holding.
  • UBS Group first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • UBS Group's 4D Molecular Therapeutics position peaked at $11.9M in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.